The Scientist - Home

The California-based company Humm has developed a “bioelectric memory patch” to improve working memory, but some experts question the efficacy of the device.

Gilead’s experimental antiviral drug shortened the average time it took COVID-19 patients to recover in a NIAID-sponsored trial. There was weak evidence that it also helped reduce deaths.

Engineering an ultra-sensitive light-activated ion channel into brain cells allows for the control of neurons in live animals without a brain-implanted light source.

The liquid biopsy, which detects cell-free tumor DNA, spotted undiagnosed cancers in some women, but had a greater number of false positives and false negatives.

Analyses from single-cell sequencing datasets support the idea that COVID-19 is not just a respiratory disease but an illness that can affect multiple organs.

The closure of visa offices, travel and immigration restrictions, and general anxiety create barriers for the international graduate students and postdocs who play a huge role in research in the United States.

Preprints from the first round of seroprevalence studies indicate that many more people have been infected with the virus than previously reported. Some of these studies also have serious design flaws.

The abrupt termination comes after the research drew President Trump’s attention for its ties to the Wuhan Institute of Virology.

Submit your new product now to have a chance at being selected for a coveted spot in The Scientist’s 2020 competition.

Early reports from hospitals document a spike in large vessel blockages, especially among people in their 30s and 40s who tested positive for the coronavirus.

Monitoring the comings and goings of aquatic life with traces of DNA in water has become an established biomonitoring technique, but scientists are now using environmental DNA to assess terrestrial animals.

Nine of the 20 pharma companies that participated in a study had experienced at least one viral contamination event between 1985 and 2018.